Shares of Kane Biotech Inc. (CVE:KNE – Get Free Report) traded down 23.1% during trading on Friday . The stock traded as low as C$0.05 and last traded at C$0.05. 159,625 shares traded hands during mid-day trading, an increase of 120% from the average session volume of 72,560 shares. The stock had previously closed at C$0.07.
Kane Biotech Trading Down 23.1%
The company has a debt-to-equity ratio of -331.42, a quick ratio of 0.39 and a current ratio of 0.80. The stock has a market capitalization of C$7.20 million, a P/E ratio of 1.25 and a beta of 0.52. The firm’s fifty day simple moving average is C$0.08 and its 200 day simple moving average is C$0.10.
Kane Biotech Company Profile
Kane Biotech Inc, a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, an antimicrobial wound gel platform; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine for treating wounds and otic infections.
Featured Stories
- Five stocks we like better than Kane Biotech
- How to Invest in Biotech Stocks
- X: 1 Reason to Bet on U.S. Steel, and 1 Reason to Hold Back
- How to Plot Fibonacci Price Inflection Levels
- 3 Oversold Stocks Flashing Bullish Reversal Signals
- What Investors Need to Know About Upcoming IPOs
- With Novo Nordisk’s CEO Out, Wall Street Wants an American Leader
Receive News & Ratings for Kane Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kane Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
